Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25092225,fasting C-peptide,"We analyzed data collected in 11 subjects with T2D [6 male, 9 white European and two of Indian ethnicity; age 59.7(12.1) years, BMI 30.1(3.9) kg/m(2), fasting C-peptide 1002.2(365.8) pmol/l, fasting plasma glucose 9.6(2.2) mmol/l, diabetes duration 8.0(6.2) years and HbA1c 8.3(0.8)%; mean(SD)] who underwent a 24-h study investigating closed-loop insulin delivery at the Wellcome Trust Clinical Research Facility, Cambridge, UK.",Pharmacokinetics of insulin lispro in type 2 diabetes during closed-loop insulin delivery. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092225/),pm,1002.2,2270,DB00046,Insulin Lispro
,25092225,time-to-peak of lispro absorption (t(max)),The time-to-peak of lispro absorption (t(max)) was 109.6 (75.5-120.5) min [median (interquartile range)] and the metabolic clearance rate (MCR(I)) 1.26 (0.87-1.56)×10(-2) l/kg/min.,Pharmacokinetics of insulin lispro in type 2 diabetes during closed-loop insulin delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092225/),min,109.6,2271,DB00046,Insulin Lispro
,19464026,peak plasma concentration (C(max)),"In 9 evaluable subjects, plasma pramlintide concentrations increased dose-proportionately; mean peak plasma concentration (C(max)) (15-microg dose, 93 +/- 9 pg/mL; 30-microg dose, 202 +/- 21 pg/mL) occurred approximately 0.3 h (median time to peak concentration) after administration.","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),[pg] / [ml],93,2983,DB00046,Insulin Lispro
,19464026,peak plasma concentration (C(max)),"In 9 evaluable subjects, plasma pramlintide concentrations increased dose-proportionately; mean peak plasma concentration (C(max)) (15-microg dose, 93 +/- 9 pg/mL; 30-microg dose, 202 +/- 21 pg/mL) occurred approximately 0.3 h (median time to peak concentration) after administration.","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),[pg] / [ml],202,2984,DB00046,Insulin Lispro
,19464026,time to peak concentration,"In 9 evaluable subjects, plasma pramlintide concentrations increased dose-proportionately; mean peak plasma concentration (C(max)) (15-microg dose, 93 +/- 9 pg/mL; 30-microg dose, 202 +/- 21 pg/mL) occurred approximately 0.3 h (median time to peak concentration) after administration.","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),h,0.3,2985,DB00046,Insulin Lispro
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),p,4,2986,DB00046,Insulin Lispro
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),p,5,2987,DB00046,Insulin Lispro
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),pg,35,2988,DB00046,Insulin Lispro
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),mg,129,2989,DB00046,Insulin Lispro
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),,132,2990,DB00046,Insulin Lispro
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),mg,217,2991,DB00046,Insulin Lispro
,20150302,GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),,7.1,13577,DB00046,Insulin Lispro
,20150302,GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),,3.9,13578,DB00046,Insulin Lispro
,20150302,time to reach GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),min,116,13579,DB00046,Insulin Lispro
,20150302,time to reach GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),min,209,13580,DB00046,Insulin Lispro
,9075793,Total absorption,"Total absorption was 97 +/- 10% for insulin, 99 +/- 7% for LysB28ProB29-human insulin, and 93 +/- 12% for AspB10LysB28ProB29-human insulin.",Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9075793/),%,97,17957,DB00046,Insulin Lispro
,9075793,Total absorption,"Total absorption was 97 +/- 10% for insulin, 99 +/- 7% for LysB28ProB29-human insulin, and 93 +/- 12% for AspB10LysB28ProB29-human insulin.",Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9075793/),%,99,17958,DB00046,Insulin Lispro
,9075793,Total absorption,"Total absorption was 97 +/- 10% for insulin, 99 +/- 7% for LysB28ProB29-human insulin, and 93 +/- 12% for AspB10LysB28ProB29-human insulin.",Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9075793/),%,93,17959,DB00046,Insulin Lispro
,30565407,AUCins,"BCLIS also demonstrated significantly higher early exposure (AUCins, 0-60 minutes) and lower late exposure (AUCins,120-600 minutes) than both other insulins.",BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30565407/),min,0-60,25782,DB00046,Insulin Lispro
,30565407,AUCins,"BCLIS also demonstrated significantly higher early exposure (AUCins, 0-60 minutes) and lower late exposure (AUCins,120-600 minutes) than both other insulins.",BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30565407/),min,120-600,25783,DB00046,Insulin Lispro
,11553186,C(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),[pM] / [l],971,47820,DB00046,Insulin Lispro
,11553186,C(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),[pM] / [l],659,47821,DB00046,Insulin Lispro
,11553186,T(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),min,46.9,47822,DB00046,Insulin Lispro
,11553186,T(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),min,94.7,47823,DB00046,Insulin Lispro
,18192544,area under the curve(0-t'),"AIR insulin exposure was reduced 34 and 41% (both P < 0.01) in asthmatic subjects (area under the curve(0-t'), 24.0 and 21.1 nmol x min x l(-1) in mild and moderate asthma subjects, respectively) compared with healthy subjects (35.2 nmol x min x l(-1)), respectively.","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),[min·nM] / [l],24.0,62244,DB00046,Insulin Lispro
,18192544,area under the curve(0-t'),"AIR insulin exposure was reduced 34 and 41% (both P < 0.01) in asthmatic subjects (area under the curve(0-t'), 24.0 and 21.1 nmol x min x l(-1) in mild and moderate asthma subjects, respectively) compared with healthy subjects (35.2 nmol x min x l(-1)), respectively.","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),[min·nM] / [l],21.1,62245,DB00046,Insulin Lispro
,18192544,area under the curve(0-t'),"AIR insulin exposure was reduced 34 and 41% (both P < 0.01) in asthmatic subjects (area under the curve(0-t'), 24.0 and 21.1 nmol x min x l(-1) in mild and moderate asthma subjects, respectively) compared with healthy subjects (35.2 nmol x min x l(-1)), respectively.","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),[min·nM] / [l],35.2,62246,DB00046,Insulin Lispro
,18192544,G(tot),"Glucodynamic (G) effects were similar in healthy and mildly asthmatic subjects (G(tot) = 38.7 and 23.4 g, respectively; P = 0.16) and were reduced in moderately asthmatic subjects (G(tot) = 10.7 g).","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),g,38.7,62247,DB00046,Insulin Lispro
,18192544,G(tot),"Glucodynamic (G) effects were similar in healthy and mildly asthmatic subjects (G(tot) = 38.7 and 23.4 g, respectively; P = 0.16) and were reduced in moderately asthmatic subjects (G(tot) = 10.7 g).","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),g,23.4,62248,DB00046,Insulin Lispro
,18192544,G(tot),"Glucodynamic (G) effects were similar in healthy and mildly asthmatic subjects (G(tot) = 38.7 and 23.4 g, respectively; P = 0.16) and were reduced in moderately asthmatic subjects (G(tot) = 10.7 g).","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),g,10.7,62249,DB00046,Insulin Lispro
,12518253,glucose concentrations,Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mM] / [l],3.2,71255,DB00046,Insulin Lispro
,12518253,glucose concentrations,Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mM] / [l],3.5,71256,DB00046,Insulin Lispro
,12518253,glucose concentrations,Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mM] / [l],3.4,71257,DB00046,Insulin Lispro
,12518253,t min,For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,59.3,71258,DB00046,Insulin Lispro
,12518253,t min,For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,63.5,71259,DB00046,Insulin Lispro
,12518253,C-peptide,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],225,71260,DB00046,Insulin Lispro
,12518253,C-peptide,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],309,71261,DB00046,Insulin Lispro
,12518253,C-peptide concentrations,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],117,71262,DB00046,Insulin Lispro
,12518253,C-peptide concentrations,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],105,71263,DB00046,Insulin Lispro
,12518253,maximal concentration,The maximal concentration of insulin was detected in both groups after 40 min (lispro 20.8 +/- 1.1 mU/l versus aspart 24.6 +/- 1.3 mU/l; p = 0.032).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mu] / [l],20.8,71264,DB00046,Insulin Lispro
,12518253,maximal concentration,The maximal concentration of insulin was detected in both groups after 40 min (lispro 20.8 +/- 1.1 mU/l versus aspart 24.6 +/- 1.3 mU/l; p = 0.032).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mu] / [l],24.6,71265,DB00046,Insulin Lispro
,12518253,t max,For insulin t max was 33.0 +/- 2.6 min in the aspart versus 33.3 +/- 2.6 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,33.0,71266,DB00046,Insulin Lispro
,12518253,t max,For insulin t max was 33.0 +/- 2.6 min in the aspart versus 33.3 +/- 2.6 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,33.3,71267,DB00046,Insulin Lispro
,24876617,root mean,SC pramlintide PK root mean square error values range from 1.98 to 10.66 pmol/L.,A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24876617/),[pM] / [l],1.98 to 10.66,75693,DB00046,Insulin Lispro
,19539098,post,The mean (SD) postprandial glucose excursion AUC at 120 minutes after the meal was significantly reduced in the group that used the device compared with the group that did not (104 [65] vs 155 [56] mg/dL/h; P < 0.005).,"Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mg] / [dl·h],104,77439,DB00046,Insulin Lispro
,19539098,T(max),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,45,77440,DB00046,Insulin Lispro
,19539098,T(max),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,78,77441,DB00046,Insulin Lispro
,19539098,time to half-maximum concentration (T(50%max)),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,20,77442,DB00046,Insulin Lispro
,19539098,time to half-maximum concentration (T(50%max)),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,28,77443,DB00046,Insulin Lispro
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],21,77444,DB00046,Insulin Lispro
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],33,77445,DB00046,Insulin Lispro
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],60,77446,DB00046,Insulin Lispro
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],55,77447,DB00046,Insulin Lispro
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],80,77448,DB00046,Insulin Lispro
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],90,77449,DB00046,Insulin Lispro
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],93,77450,DB00046,Insulin Lispro
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],118,77451,DB00046,Insulin Lispro
,19539098,Cmax,Cmax also increased significantly (118 [35] vs 86 [16] mU/L [38%]; P < 0.05).,"Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [l],118,77452,DB00046,Insulin Lispro
,19539098,Cmax,Cmax also increased significantly (118 [35] vs 86 [16] mU/L [38%]; P < 0.05).,"Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [l],86,77453,DB00046,Insulin Lispro
,14703957,time of maximum concentration tmax,"Plasma insulin concentrations increased faster (time of maximum concentration tmax 20 vs 40 minutes, p = 0.01) and were higher (standardized maximum concentration Cmax/D 13.6 vs 6.1 microU/ml/U, p = 0.01) after lispro-insulin compared to regular insulin.",Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703957/),min,20,80585,DB00046,Insulin Lispro
,14703957,time of maximum concentration tmax,"Plasma insulin concentrations increased faster (time of maximum concentration tmax 20 vs 40 minutes, p = 0.01) and were higher (standardized maximum concentration Cmax/D 13.6 vs 6.1 microU/ml/U, p = 0.01) after lispro-insulin compared to regular insulin.",Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703957/),min,40,80586,DB00046,Insulin Lispro
,14703957,standardized maximum concentration Cmax/D,"Plasma insulin concentrations increased faster (time of maximum concentration tmax 20 vs 40 minutes, p = 0.01) and were higher (standardized maximum concentration Cmax/D 13.6 vs 6.1 microU/ml/U, p = 0.01) after lispro-insulin compared to regular insulin.",Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703957/),[μu] / [ml·u],13.6,80587,DB00046,Insulin Lispro
,14703957,standardized maximum concentration Cmax/D,"Plasma insulin concentrations increased faster (time of maximum concentration tmax 20 vs 40 minutes, p = 0.01) and were higher (standardized maximum concentration Cmax/D 13.6 vs 6.1 microU/ml/U, p = 0.01) after lispro-insulin compared to regular insulin.",Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703957/),[μu] / [ml·u],6.1,80588,DB00046,Insulin Lispro
,20508081,G(tot),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg],2512.7,84501,DB00046,Insulin Lispro
,20508081,G(tot),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg],1291.9,84502,DB00046,Insulin Lispro
,20508081,R(max),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg·min],3.740,84503,DB00046,Insulin Lispro
,20508081,R(max),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg·min],1.793,84504,DB00046,Insulin Lispro
,20508081,area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[min·pM] / [l],77 150,84505,DB00046,Insulin Lispro
,20508081,area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[min·pM] / [l],53 111,84506,DB00046,Insulin Lispro
,20508081,maximum serum insulin concentration (C(max)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[pM] / [l],119,84507,DB00046,Insulin Lispro
,20508081,maximum serum insulin concentration (C(max)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[pM] / [l],68,84508,DB00046,Insulin Lispro
,22136324,time to peak insulin concentration,"Co-injection of lispro+rHuPH20 accelerated pharmacokinetics relative to lispro alone (time to peak insulin concentration, 43 vs. 74 min; P=0.0045) with increased exposure in the first hour (184% of control; P<0.0001) and reduced exposure after 2 h (67% of control; P=0.0001).",Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136324/),min,43,94352,DB00046,Insulin Lispro
,22136324,time to peak insulin concentration,"Co-injection of lispro+rHuPH20 accelerated pharmacokinetics relative to lispro alone (time to peak insulin concentration, 43 vs. 74 min; P=0.0045) with increased exposure in the first hour (184% of control; P<0.0001) and reduced exposure after 2 h (67% of control; P=0.0001).",Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136324/),min,74,94353,DB00046,Insulin Lispro
>,22136324,area under the curve for 0-4 h,"These accelerated pharmacokinetics improved both total hyperglycemic excursions (area under the curve for 0-4 h >140 mg/dL, 56% of control; P=0.048) and hypoglycemic excursions (area under the curve for 0-8 h <70 mg/dL, 34% of control; P=0.033), allowing over three times as many patients to reach the American Diabetes Association's target of peak PPG <180 mg/dL without requiring glucose treatment for hypoglycemia.",Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136324/),[mg] / [dl],140,94354,DB00046,Insulin Lispro
<,22136324,area under the curve for 0-8 h,"These accelerated pharmacokinetics improved both total hyperglycemic excursions (area under the curve for 0-4 h >140 mg/dL, 56% of control; P=0.048) and hypoglycemic excursions (area under the curve for 0-8 h <70 mg/dL, 34% of control; P=0.033), allowing over three times as many patients to reach the American Diabetes Association's target of peak PPG <180 mg/dL without requiring glucose treatment for hypoglycemia.",Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136324/),[mg] / [dl],70,94355,DB00046,Insulin Lispro
,21129323,peak plasma glucagon levels,"The relative error in the control algorithm's online estimate of the instantaneous plasma insulin level was also higher during episodes ending in hypoglycemia (50 versus 30%, p=.003), as were the peak plasma glucagon levels (183 versus 116 pg/ml, p=.007, normal range 50-150 pg/ml) and mean plasma glucagon levels (142 versus 75 pg/ml, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[pg] / [ml],183,104428,DB00046,Insulin Lispro
,21129323,peak plasma glucagon levels,"The relative error in the control algorithm's online estimate of the instantaneous plasma insulin level was also higher during episodes ending in hypoglycemia (50 versus 30%, p=.003), as were the peak plasma glucagon levels (183 versus 116 pg/ml, p=.007, normal range 50-150 pg/ml) and mean plasma glucagon levels (142 versus 75 pg/ml, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[pg] / [ml],116,104429,DB00046,Insulin Lispro
,21129323,rate of,"The rate of BG descent was also significantly greater during episodes ending in hypoglycemia (1.5 versus 1.0 mg/dl/min, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[mg] / [dl·min],1.5,104430,DB00046,Insulin Lispro
,21129323,rate of,"The rate of BG descent was also significantly greater during episodes ending in hypoglycemia (1.5 versus 1.0 mg/dl/min, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[mg] / [dl·min],1.0,104431,DB00046,Insulin Lispro
,21129323,descent,"The rate of BG descent was also significantly greater during episodes ending in hypoglycemia (1.5 versus 1.0 mg/dl/min, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[mg] / [dl·min],1.5,104432,DB00046,Insulin Lispro
,21129323,descent,"The rate of BG descent was also significantly greater during episodes ending in hypoglycemia (1.5 versus 1.0 mg/dl/min, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[mg] / [dl·min],1.0,104433,DB00046,Insulin Lispro
,8314011,maximum serum insulin level [Cmax],"Serum insulin concentrations peaked more than two times higher (maximum serum insulin level [Cmax], 698 vs. 308 pM, A vs. C) and in less than half the time (time to Cmax [Tmax], 42 vs. 101 min, A vs. C) after subcutaneous injection of zinc-free LYSPRO.","[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314011/),pM,698,106895,DB00046,Insulin Lispro
,8314011,maximum serum insulin level [Cmax],"Serum insulin concentrations peaked more than two times higher (maximum serum insulin level [Cmax], 698 vs. 308 pM, A vs. C) and in less than half the time (time to Cmax [Tmax], 42 vs. 101 min, A vs. C) after subcutaneous injection of zinc-free LYSPRO.","[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314011/),pM,308,106896,DB00046,Insulin Lispro
,8314011,time to Cmax [Tmax],"Serum insulin concentrations peaked more than two times higher (maximum serum insulin level [Cmax], 698 vs. 308 pM, A vs. C) and in less than half the time (time to Cmax [Tmax], 42 vs. 101 min, A vs. C) after subcutaneous injection of zinc-free LYSPRO.","[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314011/),min,42,106897,DB00046,Insulin Lispro
,8314011,time to Cmax [Tmax],"Serum insulin concentrations peaked more than two times higher (maximum serum insulin level [Cmax], 698 vs. 308 pM, A vs. C) and in less than half the time (time to Cmax [Tmax], 42 vs. 101 min, A vs. C) after subcutaneous injection of zinc-free LYSPRO.","[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314011/),min,101,106898,DB00046,Insulin Lispro
,8314011,time to maximum glucose infusion rate [TRmax],"At the same time, the glucose infusion rate peaked in about half the time (time to maximum glucose infusion rate [TRmax], 99 vs. 179 min, A vs. C) and was slightly but not significantly higher (maximum glucose infusion rate [Rmax], 3.1 vs.","[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314011/),min,99,106899,DB00046,Insulin Lispro
,8314011,time to maximum glucose infusion rate [TRmax],"At the same time, the glucose infusion rate peaked in about half the time (time to maximum glucose infusion rate [TRmax], 99 vs. 179 min, A vs. C) and was slightly but not significantly higher (maximum glucose infusion rate [Rmax], 3.1 vs.","[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314011/),min,179,106900,DB00046,Insulin Lispro
,8314011,maximum glucose infusion rate [Rmax],"At the same time, the glucose infusion rate peaked in about half the time (time to maximum glucose infusion rate [TRmax], 99 vs. 179 min, A vs. C) and was slightly but not significantly higher (maximum glucose infusion rate [Rmax], 3.1 vs.","[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314011/),,3.1,106901,DB00046,Insulin Lispro
,20429049,area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min,"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),[mg] / [kg],30.3,112731,DB00046,Insulin Lispro
,20429049,area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min,"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),[mg] / [kg],16.2,112732,DB00046,Insulin Lispro
,20429049,time to 10% of GIR (max) (GIR (max)-t (10%)),"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),min,9,112733,DB00046,Insulin Lispro
,20429049,time to 10% of GIR (max) (GIR (max)-t (10%)),"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),min,17,112734,DB00046,Insulin Lispro
,11347749,Peak plasma free insulin levels,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),[pM] / [l],359,116769,DB00046,Insulin Lispro
,11347749,Peak plasma free insulin levels,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),[pM] / [l],254,116770,DB00046,Insulin Lispro
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,85,116771,DB00046,Insulin Lispro
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,99,116772,DB00046,Insulin Lispro
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),[pM] / [l],213,116773,DB00046,Insulin Lispro
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),[pM] / [l],144,116774,DB00046,Insulin Lispro
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,118,116775,DB00046,Insulin Lispro
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,153,116776,DB00046,Insulin Lispro
,11347749,Time to maximal metabolic effect,Time to maximal metabolic effect was shorter with insulin lispro than with regular insulin in both patient groups (102 vs. 191 min [NP]; 105 vs. 172 min [DC]).,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,102,116777,DB00046,Insulin Lispro
,11347749,Time to maximal metabolic effect,Time to maximal metabolic effect was shorter with insulin lispro than with regular insulin in both patient groups (102 vs. 191 min [NP]; 105 vs. 172 min [DC]).,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,191,116778,DB00046,Insulin Lispro
,11347749,Time to maximal metabolic effect,Time to maximal metabolic effect was shorter with insulin lispro than with regular insulin in both patient groups (102 vs. 191 min [NP]; 105 vs. 172 min [DC]).,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,105,116779,DB00046,Insulin Lispro
,11347749,Time to maximal metabolic effect,Time to maximal metabolic effect was shorter with insulin lispro than with regular insulin in both patient groups (102 vs. 191 min [NP]; 105 vs. 172 min [DC]).,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,172,116780,DB00046,Insulin Lispro
,11347749,overall metabolic effect,"The overall metabolic effect of regular insulin but not of insulin lispro was lower in patients with diabetic nephropathy than in diabetic control patients (967 vs. 1,510 mg/kg, respectively).",Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),,96,116781,DB00046,Insulin Lispro
,11347749,overall metabolic effect,"The overall metabolic effect of regular insulin but not of insulin lispro was lower in patients with diabetic nephropathy than in diabetic control patients (967 vs. 1,510 mg/kg, respectively).",Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),,"1,510",116782,DB00046,Insulin Lispro
,26175543,Subcutaneous bioavailability,Subcutaneous bioavailability of BIL was 23%-29%; bioavailability for unconjugated PEG was 78%.,Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26175543/),%,23%-29,123536,DB00046,Insulin Lispro
,26175543,bioavailability,Subcutaneous bioavailability of BIL was 23%-29%; bioavailability for unconjugated PEG was 78%.,Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26175543/),%,78,123537,DB00046,Insulin Lispro
,10743981,2pp(ex),"Mix75/25 resulted in significantly lower values for 2pp(ex) (3.35+/-2.28 vs 4.13+/-2.26 mmol/L), Gex(max) (4.51+/-1.88 vs 5.19+/-1.98 mmol/L), and AUCex4 (8.01+/-7.02 vs 10.6+/-6.47 mmol x h/L) compared with 70/30.",Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10743981/),[mM] / [l],3.35,129457,DB00046,Insulin Lispro
,10743981,2pp(ex),"Mix75/25 resulted in significantly lower values for 2pp(ex) (3.35+/-2.28 vs 4.13+/-2.26 mmol/L), Gex(max) (4.51+/-1.88 vs 5.19+/-1.98 mmol/L), and AUCex4 (8.01+/-7.02 vs 10.6+/-6.47 mmol x h/L) compared with 70/30.",Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10743981/),[mM] / [l],4.13,129458,DB00046,Insulin Lispro
,10743981,Gex(max),"Mix75/25 resulted in significantly lower values for 2pp(ex) (3.35+/-2.28 vs 4.13+/-2.26 mmol/L), Gex(max) (4.51+/-1.88 vs 5.19+/-1.98 mmol/L), and AUCex4 (8.01+/-7.02 vs 10.6+/-6.47 mmol x h/L) compared with 70/30.",Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10743981/),[mM] / [l],4.51,129459,DB00046,Insulin Lispro
,10743981,Gex(max),"Mix75/25 resulted in significantly lower values for 2pp(ex) (3.35+/-2.28 vs 4.13+/-2.26 mmol/L), Gex(max) (4.51+/-1.88 vs 5.19+/-1.98 mmol/L), and AUCex4 (8.01+/-7.02 vs 10.6+/-6.47 mmol x h/L) compared with 70/30.",Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10743981/),[mM] / [l],5.19,129460,DB00046,Insulin Lispro
,10743981,AUCex4,"Mix75/25 resulted in significantly lower values for 2pp(ex) (3.35+/-2.28 vs 4.13+/-2.26 mmol/L), Gex(max) (4.51+/-1.88 vs 5.19+/-1.98 mmol/L), and AUCex4 (8.01+/-7.02 vs 10.6+/-6.47 mmol x h/L) compared with 70/30.",Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10743981/),[h·mM] / [l],8.01,129461,DB00046,Insulin Lispro
,10743981,AUCex4,"Mix75/25 resulted in significantly lower values for 2pp(ex) (3.35+/-2.28 vs 4.13+/-2.26 mmol/L), Gex(max) (4.51+/-1.88 vs 5.19+/-1.98 mmol/L), and AUCex4 (8.01+/-7.02 vs 10.6+/-6.47 mmol x h/L) compared with 70/30.",Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10743981/),[h·mM] / [l],10.6,129462,DB00046,Insulin Lispro
,17593235,area under the curve (GIR-AUC),"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),[mg] / [kg],102.3,129535,DB00046,Insulin Lispro
,17593235,area under the curve (GIR-AUC),"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),[mg] / [kg],83.1,129536,DB00046,Insulin Lispro
,17593235,area under the curve (GIR-AUC),"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),[mg] / [kg],158.0,129537,DB00046,Insulin Lispro
,17593235,area under the curve (GIR-AUC),"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),[mg] / [kg],112.3,129538,DB00046,Insulin Lispro
,17593235,time to 10% of,"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,1.4,129539,DB00046,Insulin Lispro
,17593235,time to 10% of,"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,1.5,129540,DB00046,Insulin Lispro
,17593235,time to 10% of,"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,1.4,129541,DB00046,Insulin Lispro
,17593235,time to 10% of,"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,1.5,129542,DB00046,Insulin Lispro
,17593235,time to 10%,"In accordance with these findings, the time to 10% of total INS-AUC was faster with glulisine compared with lispro at either dose (0.2 U/kg: 0.7 +/- 0.2 vs. 0.8 +/- 0.2 h; 0.4 U/kg: 0.8 +/- 0.2 vs. 0.9 +/- 0.2 h, p < 0.001).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,0.7,129543,DB00046,Insulin Lispro
,17593235,time to 10%,"In accordance with these findings, the time to 10% of total INS-AUC was faster with glulisine compared with lispro at either dose (0.2 U/kg: 0.7 +/- 0.2 vs. 0.8 +/- 0.2 h; 0.4 U/kg: 0.8 +/- 0.2 vs. 0.9 +/- 0.2 h, p < 0.001).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,0.8,129544,DB00046,Insulin Lispro
,17593235,time to 10%,"In accordance with these findings, the time to 10% of total INS-AUC was faster with glulisine compared with lispro at either dose (0.2 U/kg: 0.7 +/- 0.2 vs. 0.8 +/- 0.2 h; 0.4 U/kg: 0.8 +/- 0.2 vs. 0.9 +/- 0.2 h, p < 0.001).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,0.9,129545,DB00046,Insulin Lispro
,24610683,Maximal post-insulin bolus concentration,Maximal post-insulin bolus concentration was 57 mU/L on day 1 InsuPatch versus 47.6 mU/L on day 1 control (p < 0.01).,"Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],57,130150,DB00046,Insulin Lispro
,24610683,Maximal post-insulin bolus concentration,Maximal post-insulin bolus concentration was 57 mU/L on day 1 InsuPatch versus 47.6 mU/L on day 1 control (p < 0.01).,"Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],47.6,130151,DB00046,Insulin Lispro
,24610683,Maximal insulin concentration,"Maximal insulin concentration was 70.4 mU/L versus 57 mU/L, respectively (p = 0.05).","Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],70.4,130152,DB00046,Insulin Lispro
,24610683,Maximal insulin concentration,"Maximal insulin concentration was 70.4 mU/L versus 57 mU/L, respectively (p = 0.05).","Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],57,130153,DB00046,Insulin Lispro
<,24118909,peak-to-trough,"PK steady state was achieved within 7-10 days and the peak-to-trough fluctuation was <2, translating to a nearly 'peakless' glucose infusion rate at steady state and with a duration of action of at least 24 h.","Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118909/),,2,133044,DB00046,Insulin Lispro
,24118909,t1/2,Across dose levels t1/2 ranged from 44.7 to 75.5 h (~2-3 days).,"Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118909/),h,44.7 to 75.5,133045,DB00046,Insulin Lispro
,24118909,t1/2,Across dose levels t1/2 ranged from 44.7 to 75.5 h (~2-3 days).,"Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118909/),d,2-3,133046,DB00046,Insulin Lispro
,18641968,time to early half-maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,33,134613,DB00046,Insulin Lispro
,18641968,time to early half-maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,51,134614,DB00046,Insulin Lispro
,18641968,time to early half-maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,66,134615,DB00046,Insulin Lispro
,18641968,time to maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,136,134616,DB00046,Insulin Lispro
,18641968,time to maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,152,134617,DB00046,Insulin Lispro
,18641968,time to maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,193,134618,DB00046,Insulin Lispro
,18641968,AUC glucose infusion rate [GIR] 0-120 min,The metabolic activity in the first 2 h after injection was higher with ultra-fast insulin and insulin lispro than with human soluble insulin (AUC glucose infusion rate [GIR] 0-120 min: 915 +/- 301 and 781 +/- 174 vs 580 +/- 164 mg/kg; p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],915,134619,DB00046,Insulin Lispro
,18641968,AUC glucose infusion rate [GIR] 0-120 min,The metabolic activity in the first 2 h after injection was higher with ultra-fast insulin and insulin lispro than with human soluble insulin (AUC glucose infusion rate [GIR] 0-120 min: 915 +/- 301 and 781 +/- 174 vs 580 +/- 164 mg/kg; p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],781,134620,DB00046,Insulin Lispro
,18641968,AUC glucose infusion rate [GIR] 0-120 min,The metabolic activity in the first 2 h after injection was higher with ultra-fast insulin and insulin lispro than with human soluble insulin (AUC glucose infusion rate [GIR] 0-120 min: 915 +/- 301 and 781 +/- 174 vs 580 +/- 164 mg/kg; p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],580,134621,DB00046,Insulin Lispro
,18641968,AUCGIR 0-120 min,A clear dose-response relationship was observed with the three doses of ultra-fast insulin: AUCGIR 0-120 min 12 IU 915 +/- 301 vs 6 IU 718 +/- 255 vs 3 IU 524 +/- 262 mg/kg (p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],915,134622,DB00046,Insulin Lispro
,18641968,AUCGIR 0-120 min,A clear dose-response relationship was observed with the three doses of ultra-fast insulin: AUCGIR 0-120 min 12 IU 915 +/- 301 vs 6 IU 718 +/- 255 vs 3 IU 524 +/- 262 mg/kg (p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],6,134623,DB00046,Insulin Lispro
,18641968,AUCGIR 0-120 min,A clear dose-response relationship was observed with the three doses of ultra-fast insulin: AUCGIR 0-120 min 12 IU 915 +/- 301 vs 6 IU 718 +/- 255 vs 3 IU 524 +/- 262 mg/kg (p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],718,134624,DB00046,Insulin Lispro
,18641968,AUCGIR 0-120 min,A clear dose-response relationship was observed with the three doses of ultra-fast insulin: AUCGIR 0-120 min 12 IU 915 +/- 301 vs 6 IU 718 +/- 255 vs 3 IU 524 +/- 262 mg/kg (p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],3,134625,DB00046,Insulin Lispro
,18641968,AUCGIR 0-120 min,A clear dose-response relationship was observed with the three doses of ultra-fast insulin: AUCGIR 0-120 min 12 IU 915 +/- 301 vs 6 IU 718 +/- 255 vs 3 IU 524 +/- 262 mg/kg (p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],524,134626,DB00046,Insulin Lispro
,20960101,Area Under Curve (AUC(0-clamp end)),"The Area Under Curve (AUC(0-clamp end)) in Glulisine and Lispro groups were 1455.04 ± 381.88 mg/kg and 1356.25 ± 287.30 mg/kg (P > 0.05), respectively.",Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20960101/),[mg] / [kg],1455.04,136301,DB00046,Insulin Lispro
,20960101,Area Under Curve (AUC(0-clamp end)),"The Area Under Curve (AUC(0-clamp end)) in Glulisine and Lispro groups were 1455.04 ± 381.88 mg/kg and 1356.25 ± 287.30 mg/kg (P > 0.05), respectively.",Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20960101/),[mg] / [kg],1356.25,136302,DB00046,Insulin Lispro
,21355718,time to maximum insulin concentration,"Microneedle ID delivery resulted in more rapid absorption of IL, with decreased time to maximum insulin concentration (ID vs. SC: 36.0-46.4 vs. 64.3 min, P < 0.05) and higher fractional availability at early postinjection times.",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,36.0-46.4,144273,DB00046,Insulin Lispro
,21355718,time to maximum insulin concentration,"Microneedle ID delivery resulted in more rapid absorption of IL, with decreased time to maximum insulin concentration (ID vs. SC: 36.0-46.4 vs. 64.3 min, P < 0.05) and higher fractional availability at early postinjection times.",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,64.3,144274,DB00046,Insulin Lispro
,21355718,time to maximum,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,106-112,144275,DB00046,Insulin Lispro
,21355718,time to maximum,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,130,144276,DB00046,Insulin Lispro
,21355718,early half-maximal,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,29-35,144277,DB00046,Insulin Lispro
,21355718,early half-maximal,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,42,144278,DB00046,Insulin Lispro
,21355718,time to late half-maximal,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,271-287,144279,DB00046,Insulin Lispro
,21355718,time to late half-maximal,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,309,144280,DB00046,Insulin Lispro
,15170368,"k(a,L)","The best estimate for k(a,L) was found to be 0.020-0.032 h(-1), effectively unchanged across doses (0.3-1.8 IU/kg), formulations (powder vs liquid) and subjects (healthy vs diabetic), suggesting passive diffusive absorption of insulin from the lung.",Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15170368/),1/[h],0.020-0.032,155135,DB00046,Insulin Lispro
,15170368,k(,"In contrast, the values for k(mm,L) were much larger (0.5-1.6 h(-1)) and decreased with increasing inhaled dose.",Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15170368/),1/[h],0.5-1.6,155136,DB00046,Insulin Lispro
,15170368,absolute bioavailability,"As a result, the absolute bioavailability ranged from 1.5% to 4.8%.",Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15170368/),%,1.5,155137,DB00046,Insulin Lispro
,15170368,absolute bioavailability,"As a result, the absolute bioavailability ranged from 1.5% to 4.8%.",Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15170368/),%,4.8,155138,DB00046,Insulin Lispro
,23013357,Duration of action,"Duration of action was similar for detemir [23.0 (range 2.25-32) h] and NPL [22.0 (9.5-32) h], p = 0.55.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),h,23.0,157003,DB00046,Insulin Lispro
,23013357,Duration of action,"Duration of action was similar for detemir [23.0 (range 2.25-32) h] and NPL [22.0 (9.5-32) h], p = 0.55.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),h,22.0,157004,DB00046,Insulin Lispro
,23013357,"area under the curve, AUC","Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],1326,157005,DB00046,Insulin Lispro
,23013357,"area under the curve, AUC","Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],1841,157006,DB00046,Insulin Lispro
,23013357,AUC,"Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],784,157007,DB00046,Insulin Lispro
,23013357,AUC,"Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],1392,157008,DB00046,Insulin Lispro
,23013357,AUC,"Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],455,157009,DB00046,Insulin Lispro
,23013357,AUC,"Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],274,157010,DB00046,Insulin Lispro
,23013357,GIR(max),"Detemir also showed a lower and later peak of action than NPL [GIR(max) 2.0 vs. 3.2 mg/kg/min, p < 0.01; T(max) 9.1 (95% confidence interval: 3.0-14.7) vs. 7.0 h (1.8-15.2)].",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg·min],2.0,157011,DB00046,Insulin Lispro
,23013357,GIR(max),"Detemir also showed a lower and later peak of action than NPL [GIR(max) 2.0 vs. 3.2 mg/kg/min, p < 0.01; T(max) 9.1 (95% confidence interval: 3.0-14.7) vs. 7.0 h (1.8-15.2)].",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg·min],3.2,157012,DB00046,Insulin Lispro
,23013357,T(max),"Detemir also showed a lower and later peak of action than NPL [GIR(max) 2.0 vs. 3.2 mg/kg/min, p < 0.01; T(max) 9.1 (95% confidence interval: 3.0-14.7) vs. 7.0 h (1.8-15.2)].",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),h,9.1,157013,DB00046,Insulin Lispro
,23013357,T(max),"Detemir also showed a lower and later peak of action than NPL [GIR(max) 2.0 vs. 3.2 mg/kg/min, p < 0.01; T(max) 9.1 (95% confidence interval: 3.0-14.7) vs. 7.0 h (1.8-15.2)].",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),h,7.0,157014,DB00046,Insulin Lispro
,7958544,hepatic,"After MI, hepatic glucose production was more suppressed (0.7 +/- 1 vs 5.9 +/- 0.54 mumol.kg-1.min-1) and glucose utilization was less suppressed than after HI (11.6 +/- 0.65 vs 9.1 +/- 0.11 mumol.kg-1.min-1) (p < 0.05).","Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. ",QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7958544/),[μM] / [kg·min],0.7,180152,DB00046,Insulin Lispro
,7958544,glucose production,"After MI, hepatic glucose production was more suppressed (0.7 +/- 1 vs 5.9 +/- 0.54 mumol.kg-1.min-1) and glucose utilization was less suppressed than after HI (11.6 +/- 0.65 vs 9.1 +/- 0.11 mumol.kg-1.min-1) (p < 0.05).","Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7958544/),[μM] / [kg·min],0.7,180153,DB00046,Insulin Lispro
,7958544,glucose production,"After MI, hepatic glucose production was more suppressed (0.7 +/- 1 vs 5.9 +/- 0.54 mumol.kg-1.min-1) and glucose utilization was less suppressed than after HI (11.6 +/- 0.65 vs 9.1 +/- 0.11 mumol.kg-1.min-1) (p < 0.05).","Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7958544/),[μM] / [kg·min],5.9,180154,DB00046,Insulin Lispro
,7958544,glucose utilization,"After MI, hepatic glucose production was more suppressed (0.7 +/- 1 vs 5.9 +/- 0.54 mumol.kg-1.min-1) and glucose utilization was less suppressed than after HI (11.6 +/- 0.65 vs 9.1 +/- 0.11 mumol.kg-1.min-1) (p < 0.05).","Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7958544/),[μM] / [kg·min],11.6,180155,DB00046,Insulin Lispro
,7958544,glucose utilization,"After MI, hepatic glucose production was more suppressed (0.7 +/- 1 vs 5.9 +/- 0.54 mumol.kg-1.min-1) and glucose utilization was less suppressed than after HI (11.6 +/- 0.65 vs 9.1 +/- 0.11 mumol.kg-1.min-1) (p < 0.05).","Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7958544/),[μM] / [kg·min],9.1,180156,DB00046,Insulin Lispro
,9839100,Peak plasma insulin levels,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[ng] / [ml],2.6,182897,DB00046,Insulin Lispro
,9839100,Peak plasma insulin levels,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[ng] / [ml],2.2,182898,DB00046,Insulin Lispro
,9839100,Peak plasma insulin levels,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[ng] / [ml],1.9,182899,DB00046,Insulin Lispro
,9839100,total glucose infused,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],121.5,182900,DB00046,Insulin Lispro
,9839100,total glucose infused,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],135.0,182901,DB00046,Insulin Lispro
,9839100,total glucose infused,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],117.3,182902,DB00046,Insulin Lispro
,9839100,maximum glucose infusion rate (GIRmax),"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],8.3,182903,DB00046,Insulin Lispro
,9839100,maximum glucose infusion rate (GIRmax),"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],8.0,182904,DB00046,Insulin Lispro
,9839100,maximum glucose infusion rate (GIRmax),"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],7.1,182905,DB00046,Insulin Lispro
,9839100,times until peak insulin concentrations,"The times until peak insulin concentrations were similar in treatment groups A and B, but significantly shorter than in treatment group C (0.9 +/- 0.3 and 1.2 +/- 0.2 vs. 2.0 +/- 0.4 h, respectively, P = 0.042).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),h,0.9,182906,DB00046,Insulin Lispro
,9839100,times until peak insulin concentrations,"The times until peak insulin concentrations were similar in treatment groups A and B, but significantly shorter than in treatment group C (0.9 +/- 0.3 and 1.2 +/- 0.2 vs. 2.0 +/- 0.4 h, respectively, P = 0.042).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),h,1.2,182907,DB00046,Insulin Lispro
,9839100,times until peak insulin concentrations,"The times until peak insulin concentrations were similar in treatment groups A and B, but significantly shorter than in treatment group C (0.9 +/- 0.3 and 1.2 +/- 0.2 vs. 2.0 +/- 0.4 h, respectively, P = 0.042).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),h,2.0,182908,DB00046,Insulin Lispro
,9839100,times until GIRmax,"The times until GIRmax were also not different (113.9 +/- 41 and 122.0 +/- 45 vs. 209.0 +/- 51.3 min, respectively, P = 0.002).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),min,113.9,182909,DB00046,Insulin Lispro
,9839100,times until GIRmax,"The times until GIRmax were also not different (113.9 +/- 41 and 122.0 +/- 45 vs. 209.0 +/- 51.3 min, respectively, P = 0.002).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),min,122.0,182910,DB00046,Insulin Lispro
,9839100,times until GIRmax,"The times until GIRmax were also not different (113.9 +/- 41 and 122.0 +/- 45 vs. 209.0 +/- 51.3 min, respectively, P = 0.002).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),min,209.0,182911,DB00046,Insulin Lispro
,9839100,glucose infusion rate (GIR),"The glucose infusion rate (GIR) then fell to 50% GIRmax more quickly in treatment groups A and B than in treatment group C (239.9 +/- 40.5 vs. 292.4 +/- 133.3 vs. 399.5 +/- 78.3, respectively, P = 0.005).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),,239.9,182912,DB00046,Insulin Lispro
,9839100,glucose infusion rate (GIR),"The glucose infusion rate (GIR) then fell to 50% GIRmax more quickly in treatment groups A and B than in treatment group C (239.9 +/- 40.5 vs. 292.4 +/- 133.3 vs. 399.5 +/- 78.3, respectively, P = 0.005).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),,292.4,182913,DB00046,Insulin Lispro
,9839100,glucose infusion rate (GIR),"The glucose infusion rate (GIR) then fell to 50% GIRmax more quickly in treatment groups A and B than in treatment group C (239.9 +/- 40.5 vs. 292.4 +/- 133.3 vs. 399.5 +/- 78.3, respectively, P = 0.005).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),,399.5,182914,DB00046,Insulin Lispro
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,0.8,189294,DB00046,Insulin Lispro
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,0.5,189295,DB00046,Insulin Lispro
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,1,189296,DB00046,Insulin Lispro
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,1.5,189297,DB00046,Insulin Lispro
,16186270,late t(50%),"HIIP demonstrated a similar rapid onset but an extended time exposure and a prolonged duration of effect (late t(50%) 412 vs. 236 min, P < 0.001) compared with SC lispro.",Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),min,412,200856,DB00046,Insulin Lispro
,16186270,late t(50%),"HIIP demonstrated a similar rapid onset but an extended time exposure and a prolonged duration of effect (late t(50%) 412 vs. 236 min, P < 0.001) compared with SC lispro.",Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),min,236,200857,DB00046,Insulin Lispro
,16186270,insulin (t(max)),"The median insulin (t(max)) was not different between HIIP and SC lispro (45 min for both), although the median time of return to baseline for PK was apparently longer for HIIP compared with SC lispro (480 vs. 360 min).",Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),min,45,200858,DB00046,Insulin Lispro
,16186270,time of return to baseline,"The median insulin (t(max)) was not different between HIIP and SC lispro (45 min for both), although the median time of return to baseline for PK was apparently longer for HIIP compared with SC lispro (480 vs. 360 min).",Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),min,480,200859,DB00046,Insulin Lispro
,16186270,time of return to baseline,"The median insulin (t(max)) was not different between HIIP and SC lispro (45 min for both), although the median time of return to baseline for PK was apparently longer for HIIP compared with SC lispro (480 vs. 360 min).",Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),min,360,200860,DB00046,Insulin Lispro
,16186270,Relative bioavailability,Relative bioavailability and relative biopotency of HIIP were consistent across doses (8 and 9%).,Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),%,8,200861,DB00046,Insulin Lispro
,16186270,Relative bioavailability,Relative bioavailability and relative biopotency of HIIP were consistent across doses (8 and 9%).,Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),%,9,200862,DB00046,Insulin Lispro
,16186270,relative biopotency,Relative bioavailability and relative biopotency of HIIP were consistent across doses (8 and 9%).,Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),%,9,200863,DB00046,Insulin Lispro
,12060061,trough FSI,"Notably, the trough FSI at the end of the sampling periods was almost identical (day 1, 79 +/- 56 pmol/l, day 4, 77 +/- 56 pmol/l, day 11, 86 +/- 60 pmol/l).",No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060061/),[pM] / [l],79,202365,DB00046,Insulin Lispro
,12060061,trough FSI,"Notably, the trough FSI at the end of the sampling periods was almost identical (day 1, 79 +/- 56 pmol/l, day 4, 77 +/- 56 pmol/l, day 11, 86 +/- 60 pmol/l).",No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060061/),[pM] / [l],77,202366,DB00046,Insulin Lispro
,12060061,trough FSI,"Notably, the trough FSI at the end of the sampling periods was almost identical (day 1, 79 +/- 56 pmol/l, day 4, 77 +/- 56 pmol/l, day 11, 86 +/- 60 pmol/l).",No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060061/),[pM] / [l],86,202367,DB00046,Insulin Lispro
<,27528391,bioavailability,"In LDC sheep, bioavailability decreased to <2%; most of the dose was absorbed via the lymphatic system, with 88% ± 19% of the dose collected in the lymph after SC administration.",Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27528391/),%,2,212516,DB00046,Insulin Lispro
,27528391,bioavailability,"In LDC sheep, bioavailability decreased to <2%; most of the dose was absorbed via the lymphatic system, with 88% ± 19% of the dose collected in the lymph after SC administration.",Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27528391/),%,88,212517,DB00046,Insulin Lispro
>,19761358,duration of insulin action (tR(last)),The duration of insulin action (tR(last)) for ILPS at 0.8 U/kg was >23 hours and was similar to G (p = 0.114) and D (p = 0.570).,Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761358/),h,23,214521,DB00046,Insulin Lispro
,8937933,Kd,"Patient 1 showed a considerable improvement of insulin binding after receiving Lispro (26,700 vs. 5,600 receptors/monocyte; Kd 560 vs. 1,500 pM).",Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937933/),pM,560,216915,DB00046,Insulin Lispro
,8937933,Kd,"Patient 1 showed a considerable improvement of insulin binding after receiving Lispro (26,700 vs. 5,600 receptors/monocyte; Kd 560 vs. 1,500 pM).",Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937933/),pM,"1,500",216916,DB00046,Insulin Lispro
,20841613,time to lispro plasma peak (T(max)),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,48.3,252607,DB00046,Insulin Lispro
,20841613,time to lispro plasma peak (T(max)),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,55.7,252608,DB00046,Insulin Lispro
,20841613,maximal glucose infusion rate (,"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),[mg] / [kg·min],9.0,252609,DB00046,Insulin Lispro
,20841613,maximal glucose infusion rate (,"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),[mg] / [kg·min],0.6,252610,DB00046,Insulin Lispro
,20841613,maximal glucose infusion rate (,"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,69,252611,DB00046,Insulin Lispro
,20841613,maximal glucose infusion rate (,"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,130,252612,DB00046,Insulin Lispro
,20841613,GIR(max),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),[mg] / [kg·min],9.0,252613,DB00046,Insulin Lispro
,20841613,GIR(max),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),[mg] / [kg·min],0.6,252614,DB00046,Insulin Lispro
,20841613,GIR(max),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,69,252615,DB00046,Insulin Lispro
,20841613,GIR(max),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,130,252616,DB00046,Insulin Lispro
,20841613,T(max),"After 30- and 50-unit injections, T(max) (88.6 and 130.0 min, respectively) and time to GIR(max) (175 and 245 min) were further delayed and dose related (r(2) = 0.51, P = 0.0004 and r(2) = 0.76, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,88.6,252617,DB00046,Insulin Lispro
,20841613,T(max),"After 30- and 50-unit injections, T(max) (88.6 and 130.0 min, respectively) and time to GIR(max) (175 and 245 min) were further delayed and dose related (r(2) = 0.51, P = 0.0004 and r(2) = 0.76, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,130.0,252618,DB00046,Insulin Lispro
,20841613,time to GIR(max),"After 30- and 50-unit injections, T(max) (88.6 and 130.0 min, respectively) and time to GIR(max) (175 and 245 min) were further delayed and dose related (r(2) = 0.51, P = 0.0004 and r(2) = 0.76, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,175,252619,DB00046,Insulin Lispro
,20841613,time to GIR(max),"After 30- and 50-unit injections, T(max) (88.6 and 130.0 min, respectively) and time to GIR(max) (175 and 245 min) were further delayed and dose related (r(2) = 0.51, P = 0.0004 and r(2) = 0.76, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,245,252620,DB00046,Insulin Lispro
,33336850,∆AUC,"Compared with Lispro, ADO09 reduced postprandial blood glucose (ppBG) excursions by more than 95% in the first hour postmeal (mean ± SD ∆AUC BG 0-1 h: 1.4 ± 9.9 mg*h/dL vs. 43.5 ± 15.3 mg*h/dL; p < .0001).","ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[h·mg] / [dl],1.4,268693,DB00046,Insulin Lispro
,33336850,Maximum ppBG,Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).,"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[mg] / [dl],87.0,268694,DB00046,Insulin Lispro
,33336850,Maximum ppBG,Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).,"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[mg] / [dl],109.2,268695,DB00046,Insulin Lispro
,33336850,Maximum ppBG,Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).,"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[mg] / [dl],109.4,268696,DB00046,Insulin Lispro
,24504686,Time-to-maximum plasma concentration,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,18.0 to 42.0,271201,DB00046,Insulin Lispro
,24504686,Time-to-maximum plasma concentration,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,10.0-12.0,271202,DB00046,Insulin Lispro
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,18.0 to 42.0,271203,DB00046,Insulin Lispro
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,24.4-45.5,271204,DB00046,Insulin Lispro
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,10.0-12.0,271205,DB00046,Insulin Lispro
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,12.2-14.9,271206,DB00046,Insulin Lispro
,24504686,apparent clearance,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,24.4-45.5,271207,DB00046,Insulin Lispro
,24504686,apparent clearance,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),[l] / [h],1.8-2.8,271208,DB00046,Insulin Lispro
,24504686,apparent clearance,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,10.0-12.0,271209,DB00046,Insulin Lispro
,24504686,t½,"After IV administration, LY2605541's geometric mean t½ was 2.3 hours.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,2.3,271210,DB00046,Insulin Lispro
